Paper Details

  1. Home
  2. Paper Details

Pharmacotherapy of intermittent claudication.

Author: DoggrellS A

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Cilostazol, a specific inhibitor of phosphodiesterase 3 and activator of lipoprotein lipase, clearly increases pain-free and absolute walking distances in claudicants. However, cilostazol does cause minor side effects including headache, diarrhoea, loose stools and flatulence.
Paper Details　
Original Abstract of the Article :
Intermittent claudication (IC) is leg muscle pain, cramping and fatigue brought on by exercise and is the primary symptom of peripheral arterial disease. The goals of pharmacotherapy for IC are to increase the walking capacity/quality of life and to decrease rates of amputation. In 1988, pentoxifyll...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1517/14656566.2.11.1725

データ提供：米国国立医学図書館（NLM）

Pharmacotherapy of Intermittent Claudication: A Journey of Discovery

The journey to find effective treatments for cardiovascular disease is a long and winding one, with researchers constantly exploring new avenues to alleviate the symptoms and improve the quality of life for patients. This study delves into the pharmacotherapy of intermittent claudication (IC), a common symptom of peripheral arterial disease. The authors provide a comprehensive overview of the current state of knowledge, highlighting the various medications available for treating IC and their mechanisms of action. This study serves as a valuable resource for healthcare professionals seeking to optimize the management of IC.

Expanding the Therapeutic Landscape

This research expands our understanding of the therapeutic options for treating IC. The authors discuss the efficacy of various medications, including pentoxifylline, cilostazol, naftidrofuryl, and inhibitors of platelet aggregation, demonstrating their potential to improve walking capacity and reduce the risk of amputation. This study highlights the importance of considering individual patient needs and tailoring treatment strategies accordingly.

Navigating the Desert of Disease

The quest to find effective treatments for cardiovascular disease is like a camel navigating a vast and unforgiving desert. This study provides a roadmap for healthcare professionals, highlighting the various therapeutic options available and their potential benefits. By working together, we can help patients find relief and improve their quality of life, even in the face of challenging conditions.

Dr. Camel's Conclusion

This research is a testament to the ongoing progress in cardiovascular medicine. By exploring new therapeutic avenues and expanding our knowledge of the disease, we can continue to improve the lives of patients with intermittent claudication. Like a camel traversing the desert, we must remain persistent and adaptable, seeking innovative solutions to address the challenges of cardiovascular disease.

Date :
  1. Date Completed 2002-09-26
  2. Date Revised 2019-09-16
Further Info :

Pubmed ID

11825312

DOI: Digital Object Identifier

10.1517/14656566.2.11.1725

Related Literature

Article Analysis
・Side Effects of cilostazol
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.